-transparent.png){kind=logo}
We investigated the influence of L-thyroxine (L-T4) treatment over 3 weeks on biochemical markers of bone turnover in 12 healthy young men (age 25.6 +/- 1.4 years, BMI: 22.6 +/- 2.5 kg/m2). Serum parameters indicating bone formation [bone Gla protein (BGP), carboxyterminal propeptide of type I procollagen (PICP), and bone-specific alkaline phosphatase (BAP)] and bone resorption [cross-linked carboxyterminal telopeptide of type I collagen (ICTP) and the urinary excretion of pyridinoline (Pyr) and deoxypyridinoline (D-Pyr)] were measured before and after three weeks of treatment with 300 micrograms L-T4/d. T3 and T4 significantly increased and TSH decreased to almost undetectable levels even when measured with a third generation TSH assay. Markers of bone formation showed variable responses with a small but significant increase in BGP but not in PICP or BAP. In contrast, all parameters of bone resorption increased significantly with a good correlation between D-Pyr excretion and the serum parameter ICTP (r = 0.78, p < 0.0001). These changes in bone-turnover markers were not necessarily paralleled by comparable increments of other markers of tissue thyrotoxicosis (SHBG, pulse rate, VO2), suggesting a variability in tissue sensitivity. These rapid responding parameters, especially in the easily obtainable serum parameter ICTP, might be valuable tools in the evaluation of several states of thyroxine excess.
E U Frevert, and
A Biester, and
M J Müller, and
H Schmidt-Gayk, and
A von zur Mühlen, and
G Brabant
June 2010,
Zhongguo shi yan xue ye xue za zhi,
E U Frevert, and
A Biester, and
M J Müller, and
H Schmidt-Gayk, and
A von zur Mühlen, and
G Brabant
December 1991,
Journal of the American Geriatrics Society,
E U Frevert, and
A Biester, and
M J Müller, and
H Schmidt-Gayk, and
A von zur Mühlen, and
G Brabant
January 1997,
British journal of clinical pharmacology,
E U Frevert, and
A Biester, and
M J Müller, and
H Schmidt-Gayk, and
A von zur Mühlen, and
G Brabant
November 2009,
Vox sanguinis,
E U Frevert, and
A Biester, and
M J Müller, and
H Schmidt-Gayk, and
A von zur Mühlen, and
G Brabant
January 1981,
International pharmacopsychiatry,
E U Frevert, and
A Biester, and
M J Müller, and
H Schmidt-Gayk, and
A von zur Mühlen, and
G Brabant
November 1998,
The British journal of nutrition,
E U Frevert, and
A Biester, and
M J Müller, and
H Schmidt-Gayk, and
A von zur Mühlen, and
G Brabant
January 2012,
PloS one,
E U Frevert, and
A Biester, and
M J Müller, and
H Schmidt-Gayk, and
A von zur Mühlen, and
G Brabant
April 1977,
European journal of clinical investigation,
E U Frevert, and
A Biester, and
M J Müller, and
H Schmidt-Gayk, and
A von zur Mühlen, and
G Brabant
January 1988,
International clinical psychopharmacology,
E U Frevert, and
A Biester, and
M J Müller, and
H Schmidt-Gayk, and
A von zur Mühlen, and
G Brabant
November 2012,
Diabetes, obesity & metabolism,
